{"url_path":"/sec/uamy/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A RISK FACTORS.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/101538/0001104659-26-061193-index.html","accession_number":"0001104659-26-061193","cik":"0000101538","ticker":"UAMY","issuer_name":"UNITED STATES ANTIMONY CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/101538/0001104659-26-061193-index.html","primary_entity_key":"0000101538","primary_entity_name":"UNITED STATES ANTIMONY CORP"},"word_count":284,"has_tables":true,"body_markdown":"ITEM 1A. RISK FACTORS.\n\nThere have been no material changes from the risk factors previously disclosed in the Company’s Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 19, 2026, except as described below.\n\nThe Company’s receipt of funds under its Department of War award is subject to significant conditions, and failure to satisfy these conditions or obtain continued authorization could adversely impact its operations and financial condition. In March 2026, the Company was awarded up to $27.0 million in funding from the U.S. Department of War under the Defense Production Act, administered through the Defense Industrial Base Consortium (“DIBC”), to support the expansion and modernization of its domestic antimony processing operations. The award is structured as a milestone-based arrangement, with $16.2 million currently obligated and the remaining $10.8 million subject to future authorization at the discretion of the U.S. government. Payments are contingent upon the Company achieving specified project milestones, obtaining formal government approval of such milestones, and complying with ongoing requirements, including environmental, reporting, and project execution obligations.\n\nThere can be no assurance that the Company will successfully complete all required milestones, maintain compliance with all applicable conditions, or receive approval for additional funding. Any failure to meet these requirements, delays in milestone achievement or approval, changes in government priorities, or termination or modification of the agreement could result in a delay, reduction, or forfeiture of expected funding. In addition, the Company is required to fund a portion of the project costs, and if anticipated grant proceeds are not received in a timely manner or at all, the Company may be required to obtain alternative sources of financing or delay planned capital expenditures.\n\n​"}